GlassScriptPhysician profile
Jamshyd D Karlin
NPI 1003880261
$2,456.13
in general payments reported to CMS, 2019-2025
17 companies · $737 in 2025
The $737 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $352 · 2020: $209 · 2021: $49.55 · 2022: $211 · 2023: $484 · 2024: $413 · 2025: $737.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,635.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,634.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $644.72 | 2020-2025 | Cequa, Xelpros |
| Alcon Vision LLC | $422.88 | 2023-2025 | Clareon Panoptix Pro, Lensx, Clareon |
| Aerie Pharmaceuticals, INC. | $244.95 | 2019-2020 | |
| Dompe US, INC. | $213.56 | 2022-2023 | Oxervate |
| Allergan, INC. | $212.42 | 2019-2022 | |
| Abbvie INC. | $151.76 | 2022-2025 | |
| Rxsight INC | $142.97 | 2023-2025 | Rxsight Contact Lens, Rxsight Injector Cartridge, Rxsight Injector Handpiece |
| Bausch & Lomb Americas INC. | $135.06 | 2024-2025 | Miebo, Xiidra |
| Johnson & Johnson Surgical Vision, INC. | $89.37 | 2019 | |
| Glaukos Corporation | $45.56 | 2023 | |
| Tarsus Pharmaceuticals, INC. | $31.53 | 2024 | Xdemvy |
| Harrow Eye, LLC | $26.50 | 2025 | Vevye |
| Thea Pharma INC. | $23.91 | 2025 | Iyuzeh |
| Eyevance Pharmaceuticals LLC | $21.85 | 2022 | |
| Novartis Pharmaceuticals Corporation | $17.79 | 2023 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sight Sciences, INC. | $16.59 | 2021 | |
| Biotissue Holdings INC. | $14.71 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jamshyd Karlin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.